IDYA NASDAQ
IDEAYA Biosciences, Inc.
1W: -2.8%
1M: -10.4%
3M: -9.1%
YTD: -2.9%
1Y: +15.7%
3Y: +26.8%
5Y: +42.6%
$33.50
+0.62 (+1.89%)
After Hours: $34.12 (+0.62, +1.87%)
Weekly Expected Move ±5.7%
$31
$33
$35
$37
$39
Credit Risk of going bust: lower than 86% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.9%), IDEAYA Biosciences, Inc. would be worth roughly what it owes.
Total debt $29.3M against a stock market value of $3.17B.
Distance to default 11.75 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.7M (short-term plus half of long-term), stock volatility 45.5%; Altman Z'' 11.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99.9%), IDEAYA Biosciences, Inc. would be worth roughly what it owes.
Total debt $29.3M against a stock market value of $3.17B.
Distance to default 11.75 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.7M (short-term plus half of long-term), stock volatility 45.5%; Altman Z'' 11.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-07-27
Earliest Filing
2025-09-02
Latest Filing
partner: 11
licensee: 2
Counterparties (Filed by IDYA)
13 relationshipsCompanies named in IDYA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Les Laboratoires Servier | — | licensee | Exclusive license agreement for darovasertib products outside the United States with upfront payment and milestone payme | 2025-09-02 | View |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | partner | Exclusive worldwide license outside of Greater China for SHR-4849 development and commercialization. | 2024-12-30 | View |
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | — | partner | IDEAYA entered into an option and license agreement for an exclusive worldwide license to develop and commercialize a po | 2024-07-31 | View |
| Merck | MRK | partner | Clinical trial collaboration and supply agreement for IDE161 in combination with KEYTRUDA | 2024-03-12 | View |
| MSD International Business GmbH | — | partner | Signatory to the Clinical Trial Collaboration and Supply Agreement | 2024-03-12 | View |
| Jefferies LLC | JEF | partner | Sales agent for at-the-market offering program | 2024-01-19 | View |
| Gilead Sciences, Inc. | GILD | partner | Clinical study collaboration and supply agreement to evaluate IDE397 and Trodelvy combination in MTAP-deletion bladder c | 2023-12-04 | View |
| AAT TORREY 13-14, LLC | — | partner | Landlord for office lease agreement | 2023-11-17 | View |
| Jefferies LLC | JEF | partner | Sales agent for at-the-market offering program | 2023-06-30 | View |
| DW LSP 5000 Shoreline, LLC | — | partner | Landlord for a 10-year lease agreement for laboratory and office space. | 2023-06-06 | View |
| Pfizer Inc. | PFE | partner | Clinical trial collaboration and supply partner providing crizotinib for IDEAYA's Phase 1/2 and planned Phase 2/3 trials | 2023-05-16 | View |
| Novartis | NVSEF | licensee | Holds an exclusive, worldwide license to darovasertib from IDEAYA. | 2023-05-16 | View |
| Amgen Inc. | AMGN | partner | Clinical Trial Collaboration and Supply Agreement for IDE397/AMG 193 Combination Study | 2022-07-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Shareholder Vote; Other Events | View | |
| 2026-06-10 | Other Events; Exhibits | View | |
| 2026-06-03 | Other Events | View | |
| 2026-06-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-05-05 | Other Events; Exhibits | View | |
| 2026-04-13 | Other Events | View | |
| 2026-04-09 | Other Events | View | |
| 2026-02-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-12 | Other Events | View | |
| 2025-12-12 | Termination of Material Definitive Agreement | View | |
| 2025-12-05 | Other Events | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-20 | Other Events | View | |
| 2025-09-08 | Other Events | View | |
| 2025-09-02 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-27 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR